Antimicrobial peptides as novel anti-tuberculosis therapeutics.

@article{Silva2016AntimicrobialPA,
  title={Antimicrobial peptides as novel anti-tuberculosis therapeutics.},
  author={J. Silva and R. Appelberg and F. M. Gama},
  journal={Biotechnology advances},
  year={2016},
  volume={34 5},
  pages={
          924-940
        }
}
Tuberculosis (TB), a disease caused by the human pathogen Mycobacterium tuberculosis, has recently joined HIV/AIDS as the world's deadliest infectious disease, affecting around 9.6 million people worldwide in 2014. Of those, about 1.2 million died from the disease. Resistance acquisition to existing antibiotics, with the subsequent emergence of Multi-Drug Resistant mycobacteria strains, together with an increasing economic burden, has urged the development of new anti-TB drugs. In this scope… Expand
A review on anti‐tuberculosis peptides: Impact of peptide structure on anti‐tuberculosis activity
Silver Nanoparticles for the Therapy of Tuberculosis
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 206 REFERENCES
Antimicrobial peptides: an overview of a promising class of therapeutics
Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis
Characterization of Antimicrobial Peptides toward the Development of Novel Antibiotics
Targeting Mycobacterium tuberculosis and Other Microbial Pathogens Using Improved Synthetic Antibacterial Peptides
Road to clinical efficacy: challenges and novel strategies for antimicrobial peptide development.
  • R. Eckert
  • Medicine, Biology
  • Future microbiology
  • 2011
New old challenges in tuberculosis: potentially effective nanotechnologies in drug delivery.
...
1
2
3
4
5
...